Infectious disease investigator Nahid Bhadelia, MD says its diverse samples offer the potential to “understand what is driving disparities in COVID-19 outcomes and bridge them.”
The efficacy of treatment versus the prevalence of the condition in Black patients adds evidence to the pile that more diversity is needed in clinical trials.
It is expected that by 2030, more than 257,000 people with opioid use disorder will have died from endocarditis associated with injection drug use.
Researchers have identified properties in placenta tissue that may play an important role in preventing the transmission of COVID-19 from a mother with the virus to her fetus.
Clinical trials of Gabby, a digital conversation agent, found it increased Black women's engagement in care known to improve birth outcomes.